文献速递脑血管病

桥接治疗中纤维蛋白原耗竭性凝血病与出血转化相关

Fibrinogen Depletion Coagulopathy and Hemorrhagic Transformation in Acute Ischemic Stroke Treated With Bridging Therapy.
PubMed 文献 · Stroke · 2025-05-21

该回顾性研究分析296例大血管闭塞急性缺血性卒中患者,发现桥接治疗中纤维蛋白原耗竭性凝血病(FDC)与任何出血转化、症状性出血转化、实质血肿及3个月死亡风险升高独立相关;替奈普酶组未发生FDC。

要点

  • 桥接治疗中FDC发生率为18.2%,与静脉溶栓使用强相关。
  • FDC与任何出血转化风险独立相关(aOR 2.33)。
  • 替奈普酶组FDC发生率为0%,阿替普酶组为39.3%。

核心结论

  • 桥接治疗后FDC是常见事件,与任何出血转化、症状性出血转化、实质血肿及3个月死亡风险升高相关。
  • 本队列中替奈普酶静脉溶栓后未发生FDC,提示溶栓药物纤维蛋白特异性可能在其发生中起关键作用。

研究设计与样本

  • 回顾性分析前瞻性收集的296例大血管闭塞急性缺血性卒中患者数据,接受单独EVT或桥接治疗。
  • FDC定义为EVT开始时纤维蛋白原<2.0 g/L且较基线绝对下降>1.0 g/L。
  • 主要结局为24至36小时内任何出血转化;次要结局包括症状性出血转化、实质血肿及3个月死亡。

主要发现

  • 296例中102例(34.5%)发生出血转化,54例(18.2%)发生FDC。
  • FDC与静脉溶栓使用强相关:溶栓组53/161(32.9%)vs 非溶栓组1/135(0.7%),P<0.01。
  • 桥接治疗患者中,FDC与任何出血转化独立相关(aOR 2.33,95%CI 1.11-4.91)。
  • 桥接治疗患者中,FDC与症状性出血转化(aOR 3.35,95%CI 1.20-9.40)、实质血肿(aOR 2.87,95%CI 1.14-7.24)及3个月死亡(aOR 3.82,95%CI 1.47-9.93)独立相关。
  • 替奈普酶组26例中0例发生FDC,阿替普酶组135例中53例(39.3%)发生FDC,P<0.01。

临床怎么用

  • 桥接治疗中需关注EVT开始时纤维蛋白原水平及较基线下降幅度以识别FDC。
  • FDC患者应警惕出血转化、实质血肿及3个月死亡风险升高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemorrhagic transformation (HT) frequently occurs in acute ischemic stroke patients with a large vessel occlusion undergoing endovascular therapy (EVT), significantly impacting functional outcomes. We aimed to determine whether an early fibrinogen depletion coagulopathy (FDC) was associated with HT following bridging therapy (ie, intravenous thrombolysis [IVT] followed by EVT), and to identify its associated factors. METHODS: We retrospectively analyzed prospectively collected data from 296 patients with acute ischemic stroke with a large vessel occlusion who underwent EVT alone or bridging therapy, with fibrinogen levels measured both before baseline imaging and at the start of the EVT procedure. FDC was defined as a fibrinogen level <2.0 g/L at the start of the EVT procedure, with an absolute decrease >1.0 g/L from baseline. The primary outcome was the occurrence of any HT at 24 to 36 hours. Secondary outcomes included symptomatic HT, parenchymal hematomas, and 3-month mortality. The relationships between FDC and outcomes were studied using multivariable logistic regression analyses, adjusting for relevant confounders. We also studied baseline characteristics associated with FDC occurrence. RESULTS: Of the 296 patients enrolled, 102 (34.5%) experienced HT, and 54 (18.2%) developed FDC. FDC was strongly associated with IVT use (53/161 [32.9%] versus 1/135 [0.7%] in IVT-treated and non-IVT-treated patients, respectively; P<0.01). In patients receiving bridging therapy, FDC occurrence was independently associated with any HT (adjusted odds ratio, 2.33 [95% CI, 1.11-4.91]), symptomatic HT (adjusted odds ratio, 3.35 [95% CI, 1.20-9.40]), parenchymal hematomas (adjusted odds ratio, 2.87 [95% CI, 1.14-7.24]), and 3-month mortality (adjusted odds ratio, 3.82 [95% CI, 1.47-9.93]). None of the 26 patients who received tenecteplase experienced FDC, compared with 53 of 135 (39.3%) patients treated with alteplase (P<0.01). CONCLUSIONS: Following bridging therapy, FDC is a frequent event associated with increased risks of any HT, symptomatic HT, parenchymal hematomas, and 3-month mortality. FDC did not occur following IVT with tenecteplase in our cohort, suggesting that the fibrin specificity of thrombolytic agents may play a pivotal role in its development.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Pauillac N, Faille D, Solo Nomenjanahary M, et al. Fibrinogen Depletion Coagulopathy and Hemorrhagic Transformation in Acute Ischemic Stroke Treated With Bridging Therapy. Stroke. 2025. PMID: 40400131. doi:10.1161/STROKEAHA.125.051230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。